CD274 and non-small cell lung carcinoma: In two phase 3 studies comparing the efficacies of nivolumab versus docetaxel in advanced squamous (CheckMate 017) [4] and nonsquamous (CheckMate 057) [3] NSCLC that were resistant to platinum-based therapy, nivolumab was found to be significantly better than docetaxel in response rate, overall survival, and progression-free survival, regardless of intratumoral PD-L1 expression levels.